AKT1 and prostate neoplasm: The fairly common finding of PTEN loss (41.7%), plus the significant association with recurrence, suggests a potential role for AKT inhibition alongside androgen deprivation therapy (ADT) and radiotherapy in patients with prostate tumours showing PTEN loss.